WallStSmart

IQVIA Holdings Inc (IQV)vsPrecipio Inc (PRPO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

IQVIA Holdings Inc generates 76682% more annual revenue ($16.31B vs $21.24M). IQV leads profitability with a 8.3% profit margin vs -8.5%. IQV earns a higher WallStSmart Score of 72/100 (B).

IQV

Strong Buy

72

out of 100

Grade: B

Growth: 6.0Profit: 7.0Value: 10.0Quality: 4.3
Piotroski: 4/9Altman Z: 1.33

PRPO

Avoid

26

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

IQVUndervalued (+49.1%)

Margin of Safety

+49.1%

Fair Value

$348.46

Current Price

$165.64

$182.82 discount

UndervaluedFair: $348.46Overvalued

Intrinsic value data unavailable for PRPO.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IQV3 strengths · Avg: 8.3/10
Return on EquityProfitability
21.4%9/10

Every $100 of equity generates 21 in profit

PEG RatioValuation
0.978/10

Growing faster than its price suggests

EPS GrowthGrowth
23.6%8/10

Earnings expanding 23.6% YoY

PRPO1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
27.3%8/10

Revenue surging 27.3% year-over-year

Areas to Watch

IQV1 concerns · Avg: 2.0/10
Altman Z-ScoreHealth
1.332/10

Distress zone — elevated risk

PRPO4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$31.61M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-14.8%2/10

ROE of -14.8% — below average capital efficiency

Free Cash FlowQuality
$-44,0002/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : IQV

The strongest argument for IQV centers on Return on Equity, PEG Ratio, EPS Growth. Revenue growth of 10.3% demonstrates continued momentum. PEG of 0.97 suggests the stock is reasonably priced for its growth.

Bull Case : PRPO

The strongest argument for PRPO centers on Revenue Growth. Revenue growth of 27.3% demonstrates continued momentum.

Bear Case : IQV

The primary concerns for IQV are Altman Z-Score.

Bear Case : PRPO

The primary concerns for PRPO are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

IQV profiles as a value stock while PRPO is a growth play — different risk/reward profiles.

IQV carries more volatility with a beta of 1.41 — expect wider price swings.

PRPO is growing revenue faster at 27.3% — sustainability is the question.

IQV generates stronger free cash flow (561M), providing more financial flexibility.

Bottom Line

IQV scores higher overall (72/100 vs 26/100) and 10.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

IQVIA Holdings Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.

Precipio Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Precipio, Inc., a cancer diagnostic and reagent technology company, provides diagnostic products and services in the United States oncology market. The company is headquartered in New Haven, Connecticut.

Want to dig deeper into these stocks?